Aplastic Anemia

Detailed Overview

The disease represents a profound failure of hematopoietic stem cells. In most acquired cases, it is an autoimmune condition where autoreactive T-lymphocytes target and destroy hematopoietic stem and progenitor cells in the bone marrow. This massive destruction leaves the marrow essentially empty, replaced by fat. As a result, the body cannot produce adequate red blood cells to carry oxygen, white blood cells to fight infection, or platelets to stop bleeding. Without intensive treatment such as immunosuppressive therapy or a bone marrow transplant, severe aplastic anemia is rapidly fatal due to overwhelming infection or hemorrhage.

Epidemiology & Demographics

Incidence is rare, roughly 2 cases per million individuals annually in Western countries, with a higher rate in Asia (approx. 7 per million). It has a biphasic age distribution: a peak in young adults (15-25 years) and a second peak in older adults (>60 years).

Etiological Mechanism

Idiopathic (autoimmune) in 65-70% of cases. Secondary causes include drug exposures (chloramphenicol, carbamazepine, NSAIDs), toxic chemicals (benzene), viral infections (seronegative acute hepatitis, EBV, HIV), and radiation.

Primary Causes

Idiopathic immune-mediated stem cell destruction

Drugs (e.g., Chloramphenicol, Carbamazepine, Gold salts)

Toxins (Benzene, insecticides)

Viral infections (Non-A, Non-B, Non-C Hepatitis)

• Occupational Exposure: Working closely with benzene-containing industrial solvents.
• Recent viral hepatitis: Hepatitis-associated aplastic anemia usually presents 2-3 months after an episode of acute liver inflammation.
• Inherited telomeropathies: Short telomere syndromes predispose to marrow failure.

1. An environmental trigger (virus, drug) alters hematopoietic stem cell (HSC) antigens, or there is an intrinsic stem cell defect. 2. A dysregulated immune response occurs, activating cytotoxic CD8+ T-cells. 3. These T-cells expand clonally and migrate to the bone marrow. 4. They secrete massive amounts of inhibitory cytokines, primarily Interferon-gamma (IFN-γ) and Tumor Necrosis Factor-alpha (TNF-α). 5. These cytokines induce apoptosis in HSCs and profoundly inhibit hematopoiesis. 6. The stem cell pool is decimated, and the marrow space fills with adipocytes. The lack of mature cell production results in peripheral pancytopenia.

Characteristic Clinical Presentation

• Progressive Fatigue and Weakness: Due to severe, uncompensated anemia (lack of red blood cells).
• Mucosal Bleeding: Gingival bleeding, epistaxis, or heavy menstrual bleeding due to severe thrombocytopenia.
• Recurrent or Severe Infections: Bacterial or fungal infections resulting from profound neutropenia. Often presents as high fever without localizing signs.

Physical Examination Signs

• Petechiae and Ecchymosis
• Pallor
• Absence of Hepatosplenomegaly

• Overwhelming Sepsis: Often fungal (Aspergillus) or gram-negative bacterial, leading cause of death.
• Intracranial Hemorrhage: Spontaneous bleeding into the brain due to extreme thrombocytopenia.
• Clonal Evolution: 10-15% of survivors develop Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML) years later.

Diagnostic Criteria & Guidelines

Requires a bone marrow trephine biopsy demonstrating profound hypocellularity (mostly fat spaces) and absence of malignant infiltration or reticulin fibrosis, accompanied by peripheral pancytopenia.

Differential Diagnosis

• Acute Leukemia (AML/ALL)
• Myelodysplastic Syndromes (MDS)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)
• Severe Vitamin B12 / Folate Deficiency

Laboratory Tests & Biomarkers

• Complete Blood Count: Pancytopenia: low WBC, low RBC, low Platelets. The anemia is normocytic or macrocytic.
• Reticulocyte Count: Profoundly low (absolute reticulocytes < 20,000/mcL), reflecting failure of marrow response.
• Peripheral Smear: Shows normal looking red and white cells, just extremely few of them. No blasts or abnormal cells.

Imaging Modalities & Findings

• Not generally used for primary diagnosis: Diagnosis is strictly via bone marrow biopsy.

• Non-Severe
  Hypocellular marrow but does not meet criteria for severe. Often monitored and treated supportively.
• Severe (SAA)
  Bone marrow cellularity < 25%, plus 2 of 3: ANC < 500/mcL, Platelets < 20,000/mcL, Reticulocytes < 20,000/mcL.
• Very Severe (vSAA)
  Meets criteria for severe SAA, but ANC is < 200/mcL. Highest risk of fatal infection.

Second-Line & Adjunctive Therapy

For patients who fail initial IST: A second course of IST (using Rabbit ATG), Matched Unrelated Donor (MUD) Stem Cell Transplant, or Alemtuzumab.

Surgical & Procedural Management

Bone Marrow Transplantation involves central line placement. No other surgical intervention for the disease itself.

Recommended Lifestyle Changes

• Strict avoidance of crowds, sick individuals, and raw/undercooked foods due to neutropenia.
• Avoid contact sports or activities with fall risk due to bleeding tendency.
• Use soft-bristle toothbrushes and avoid flossing.

Patient Counseling & Advice

Treatment response to IST is slow, often taking 3-6 months. Patients remain transfusion-dependent during this period. Explain the lifetime risk of evolving into leukemia or PNH.

Follow-Up & Monitoring Schedule

Weekly or biweekly CBC counts. Monthly liver and kidney function tests (monitoring Cyclosporine toxicity). Annual bone marrow biopsy to monitor for clonal evolution to MDS/AML.

Preventive Strategies

Avoid exposure to known myelotoxins (benzene, agricultural pesticides).

Untreated severe aplastic anemia is usually fatal within 6 months. With Matched Sibling HSCT, 5-year survival is >80%. With modern IST + Eltrombopag, response rates are 70-80%, though relapses can occur.